NEWS RELEASE 04.19.2021 Arrow

Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation

NEWS RELEASE 04.19.2021 Arrow

Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing

NEWS RELEASE 04.16.2021 Arrow

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

NEWS RELEASE 03.30.2021 Arrow

Amgen to Acquire Rodeo Therapeutics Corporation

NEWS RELEASE 03.11.2021 Arrow

Amgen To Present At The Oppenheimer 31st Annual Healthcare Conference

NEWS RELEASE 03.04.2021 Arrow

Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash

NEWS RELEASE 03.03.2021 Arrow

Amgen Announces 2021 Second Quarter Dividend

NEWS RELEASE 03.02.2021 Arrow

BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

NEWS RELEASE 02.26.2021 Arrow

Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma

NEWS RELEASE 02.24.2021 Arrow

Amgen To Present At The Cowen 41st Annual Healthcare Conference

NEWS RELEASE 02.22.2021 Arrow

Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting

NEWS RELEASE 02.22.2021 Arrow

Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis

NEWS RELEASE 02.16.2021 Arrow

FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

NEWS RELEASE 02.09.2021 Arrow

Amgen To Present At Guggenheim Healthcare Talks Oncology Day

NEWS RELEASE 02.03.2021 Arrow

Amgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups

NEWS RELEASE 02.02.2021 Arrow

Amgen Reports Fourth Quarter And Full Year 2020 Financial Results

NEWS RELEASE 01.29.2021 Arrow

Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China

NEWS RELEASE 01.28.2021 Arrow

Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results

NEWS RELEASE 01.28.2021 Arrow

Amgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NEWS RELEASE 01.26.2021 Arrow

Amgen To Webcast Investor Meeting At 2020 World Conference on Lung Cancer

NEWS RELEASE 01.12.2021 Arrow

Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020

NEWS RELEASE 01.11.2021 Arrow

Amgen To Achieve Carbon Neutrality By 2027

NEWS RELEASE 01.06.2021 Arrow

Amgen To Present At The 39th Annual J.P. Morgan Healthcare Conference

Earnings

Show all
ALL RESULTS 

Data as of:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

MORE STOCK